ST Asia signs licensing agreement with PharmaMar for anti-cancer compound lurbinectedin

Singapore-based biopharmaceutical company Specialised Therapeutics Asia (ST Asia) will commercialise a new anti-cancer compound known as lurbinectedin (PM1183) throughout South East Asia, following a second major licensing deal with Spanish pharmaceu …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news